The role of neutrophils in the development and outcome of zygomycosis in haematological patients

Clinical Microbiology and Infection

Volumn 15, Issue SUPPL. 5, 2009, Pages 33-36

  Pagano, L ^a   Valentini, C G ^a   Fianchi, L ^a   Caira, M ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Neutropenia; Zygomycetes

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; POSACONAZOLE; VORICONAZOLE;

ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; FUNGAL VIRULENCE; FUNGUS HYPHAE; GRANULOCYTE TRANSFUSION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION RISK; MACROPHAGE; MUCORMYCOSIS; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHIZOPUS ORYZAE; ZYGOMYCETES;

ZYGOMYCETES;

HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOCOMPROMISED HOST; NEUTROPHILS; STEM CELL TRANSPLANTATION; ZYGOMYCOSIS;

EID: 70349997516     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.02977.x     Document Type: Review

References (22)

1. Pagano L, Offidani M, Fianchi L. Mucormycosis in hematologic patients. Haematologica 2004, 89:207-214.
2. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in haematopoietic stem cell transplant recipients. Clin Infect Dis 2002, 34:909-917.
3. Diamond RD, Haudenschild CC, Erickson NF. Monocyte-mediated damage to Rhizopus oryzae hyphae in vitro. Infect Immun 1982, 38:292-297.
4. Chamilos G, Lewis RE, Lamaris G, Walsh TJ, Kontoyiannis DP. Zygomycetes hyphae trigger an early, robust pro-inflammatory response in human polymorphonuclear neutrophils through toll-like receptor 2 induction but display relative resistance to oxidative damage. Antimicrob Agents Chemother 2008, 52:722-724.
5. Bellocchio S, Gaziano R, Bozza S. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. J Antimicrob Chemother 2005, 55:214-222.
6. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukaemia. Ann Intern Med 1966, 64:328-340.
7. Pagano L, Ricci P, Tonso A. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto). Br J Haematol 1997, 99:331-336.
8. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary care cancer centre. Clin Infect Dis 2000, 30:851-856.
9. Bethge WA, Schmalzing M, Stuhler G. Mucormycoses in patients with hematologic malignancies: an emerging fungal infection. Haematologica 2005, 90(Suppl):62-64.
10. Kara IO, Tasova Y, Uguz A, Sahin B. Mucormycosis-associated fungal infections in patients with haematologic malignancies. Int J Clin Pract 2009, 134-139.
11. Kontoyiannis DP, Lionakis MS, Lewis RE. Zygomycosis in a tertiary-care cancer centre in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005, 191(8):1350-1360.
12. Simitsopoulou M, Roilides E, Maloukou A, Gil-Lamaignere C, Walsh TJ. Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leukocytes for antifungal activity against Zygomycetes. Mycoses 2008, 51:147-154.
13. Gil-Lamaignere C, Roilides E, Maloukou A, Georgopoulou I, Petrikkos G, Walsh TJ. Amphotericin B lipid complex exerts additive antifungal activity in combination with polymorphonuclear leukocytes against Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother 2002, 50:1027-1030.
14. Roden MM, Zaoutis TE, Buchanan WL. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005, 41:634-653.
15. Sadfar A, Rodriguez GH, Lichtiger B. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer 2006, 106(12):2664-2671.
16. Sadfar A, Hanna HA, Boktour M. Impact of high-dose granulocyte transfusions in patients with cancer with candidaemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. Cancer 2004, 101:2859-2865.
17. Dignani MC, Anaissie EJ, Hester JP. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia 1997, 11:1621-1630.
18. Price TH, Bowden RA, Boeckn M. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in haematopoietic stem cell transplantation. Blood 2000, 95:3302-3309.
19. Hubel K, Carter RA, Liles WC. Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion 2002, 42:1414-1421.
20. Mousset S, Hermann S, Klein SA. Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol 2005, 84:734-741.
21. Gleissner B, Schilling A, Anagnostopolous I, Sihel I, Thiel E. Improved outcome of zygomycosis in patients with haematological diseases?. Leuk Lymphoma 2004, 45:1351-1360.
22. Greenberg RN, Mullane K, Van Burik JA. Posaconazole as savage therapy for zygomycosis. Antimicrob Agents Chemother 2006, 50:126-133.